SUBSCRIBE
SUBSCRIBE
News   FDA

U.S. Denies Approval of XenoPort, Inc., GlaxoSmithKline RLS Drug; Xenoport

February 18, 2010 | 
1 min read
Bookmark and Share

Reuters -- U.S. regulators have denied approval for a drug from XenoPort (XNPT.O) and GlaxoSmithKline (GSK.L) to treat restless legs syndrome because of a potential link to cancer found in rats.
FDA Approvals Regulatory
GSK
MORE ON THIS TOPIC
Vector illustration
Manufacturing
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
September 24, 2026
 · 
2 min read
 · 
Nick Paul Taylor
Cartoon insulin pen injection and blood glucose, 3d rendering. 3d illustration.
Approvals
Eli Lilly’s weekly insulin shot cleared by FDA, setting up another front in Novo rivalry
September 24, 2026
 · 
1 min read
 · 
Annalee Armstrong
Human kidney made out of lines. Medical Concept. 3D Rendering.
Kidney disease
Roche-Ionis’ RNA therapy reduces kidney disease marker, opening path to swift FDA nod
September 23, 2026
 · 
2 min read
 · 
Annalee Armstrong
FDA
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
September 23, 2026
 · 
2 min read
 · 
Jef Akst